University of Alberta

Inflabloc Pharmaceuticals, Inc.

Frederick West

John Mercer

Tina Grant

Andrei Manolescu

Chris Cheeseman

Brendan Trayner

Barbara A Araneo

Weiping Li

David J Marchant

Bren Jordan P Atienza

Lionel D Jensen

Ned M Weinshenker

The present disclosure relates to 2-(3-indoyl)indolin-3-one derivatives of the natural product isatisine A, synthesized from dual catalytic synthesis on metallocarbene-azide cascade chemistry, useful for treating a subject having or suspected of having an infectious disease, wherein the infection disease is caused by a virus, wherein the virus is from the family flaviviridae or paramyxoviridae.

Treatment of infectious disease

The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.

Fluorinated fructose derivatives for PET imaging

The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5'-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.

Cobalamin conjugates for anti-tumor therapy

Growing community of inventors

Edmonton, Canada

Frederick West